Genome-Wide mRNA Expression Analysis of Hepatic Adaptation to High-Fat Diets Reveals Switch from an Inflammatory to Steatotic Transcriptional Program
暂无分享,去创建一个
K. V. van Dijk | P. D. de Groot | M. V. van Erk | M. Radonjic | B. van Ommen | Jorn R. de Haan | S. V. D. van den Berg | Michael Müller | K. W. van Dijk | Philip J. de Groot
[1] J. Kramer,et al. Ectonucleoside Triphosphate Diphosphohydrolase Type 5 (Entpd5)-Deficient Mice Develop Progressive Hepatopathy, Hepatocellular Tumors, and Spermatogenic Arrest , 2009, Veterinary pathology.
[2] Peter Tontonoz,et al. Integration of metabolism and inflammation by lipid-activated nuclear receptors , 2008, Nature.
[3] F. Tinahones,et al. Fat overload aggravates oxidative stress in patients with the metabolic syndrome , 2008, European journal of clinical investigation.
[4] R. Medzhitov. Origin and physiological roles of inflammation , 2008, Nature.
[5] F. Gonzalez,et al. Hepatic steatosis in leptin-deficient mice is promoted by the PPARgamma target gene Fsp27. , 2008, Cell metabolism.
[6] A. Alcamí,et al. NF-κB-Mediated Activation of the Chemokine CCL22 by the Product of the Human Cytomegalovirus Gene UL144 Escapes Regulation by Viral IE86 , 2008, Journal of Virology.
[7] T. Luedde,et al. Hepatic NF-κB essential modulator deficiency prevents obesity-induced insulin resistance but synergizes with high-fat feeding in tumorigenesis , 2008, Proceedings of the National Academy of Sciences.
[8] C. Glass,et al. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. , 2007, Trends in immunology.
[9] Age K Smilde,et al. Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis , 2007, Genome Biology.
[10] C. Glass,et al. PPARs and molecular mechanisms of transrepression. , 2007, Biochimica et biophysica acta.
[11] Lewis C. Cantley,et al. AKT/PKB Signaling: Navigating Downstream , 2007, Cell.
[12] J. Schölmerich,et al. High‐fat Diets: Modeling the Metabolic Disorders of Human Obesity in Rodents , 2007, Obesity.
[13] T. Luedde,et al. Deletion of NEMO/IKKγ in Liver Parenchymal Cells Causes Steatohepatitis and Hepatocellular Carcinoma , 2007 .
[14] B. Staels,et al. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors , 2007, Nature Clinical Practice Endocrinology &Metabolism.
[15] G. Hotamisligil,et al. Inflammation and metabolic disorders , 2006, Nature.
[16] D. Brenner,et al. Loss of MMP 13 attenuates murine hepatic injury and fibrosis during cholestasis , 2006, Hepatology.
[17] J. Mesirov,et al. GenePattern 2.0 , 2006, Nature Genetics.
[18] Wenxuan Zhong,et al. A data-driven clustering method for time course gene expression data , 2006, Nucleic acids research.
[19] Ramón Díaz-Uriarte,et al. Gene selection and classification of microarray data using random forest , 2006, BMC Bioinformatics.
[20] R. Myers,et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data , 2005, Nucleic acids research.
[21] T. Okumura,et al. Increased expression of PPARγ in high fat diet-induced liver steatosis in mice , 2005 .
[22] R. Frants,et al. Genomic analysis of the response of mouse models to high-fat feeding shows a major role of nuclear receptors in the simultaneous regulation of lipid and inflammatory genes. , 2005, Atherosclerosis.
[23] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[24] 刘金明,et al. IL-13受体α2降低血吸虫病肉芽肿的炎症反应并延长宿主存活时间[英]/Mentink-Kane MM,Cheever AW,Thompson RW,et al//Proc Natl Acad Sci U S A , 2005 .
[25] K. Wellen,et al. Inflammation, stress, and diabetes. , 2005, The Journal of clinical investigation.
[26] B. Teusink,et al. Acute inhibition of hepatic beta-oxidation in APOE*3Leiden mice does not affect hepatic VLDL secretion or insulin sensitivity. , 2005, Journal of lipid research.
[27] S. Shoelson,et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB , 2005, Nature Medicine.
[28] M. Miyazaki,et al. Reduced Adiposity and Liver Steatosis by Stearoyl-CoA Desaturase Deficiency Are Independent of Peroxisome Proliferator-activated Receptor-α* , 2004, Journal of Biological Chemistry.
[29] J. Horton,et al. Molecular mediators of hepatic steatosis and liver injury. , 2004, The Journal of clinical investigation.
[30] S Miyano,et al. Open source clustering software. , 2004, Bioinformatics.
[31] P. Kopelman,et al. New thoughts on managing obesity , 2004, Gut.
[32] Gordon K Smyth,et al. Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .
[33] P. Quax,et al. Toll-Like Receptor 4 Is Involved in Outward Arterial Remodeling , 2004, Circulation.
[34] M. O’connor,et al. Peroxisome Proliferator Activator Receptor-γ Ligands, 15-Deoxy-Δ12,14-Prostaglandin J2 and Ciglitazone, Reduce Systemic Inflammation in Polymicrobial Sepsis by Modulation of Signal Transduction Pathways 1 , 2003, The Journal of Immunology.
[35] M. Reitman,et al. Liver Peroxisome Proliferator-activated Receptor γ Contributes to Hepatic Steatosis, Triglyceride Clearance, and Regulation of Body Fat Mass* , 2003, Journal of Biological Chemistry.
[36] Brad T. Sherman,et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.
[37] J. Saurat,et al. Peroxisome proliferator‐activated receptors in cutaneous biology , 2003, The British journal of dermatology.
[38] Z. Bloomgarden,et al. Inflammation and insulin resistance. , 2003, Diabetes care.
[39] Sam J. P. Gobin,et al. Regulation of human β2-microglobulin transactivation in hematopoietic cells , 2003 .
[40] S. Kersten,et al. Nutrigenomics: goals and strategies , 2003, Nature Reviews Genetics.
[41] Kunihiro Matsumoto,et al. Cytokines suppress adipogenesis and PPAR-γ function through the TAK1/TAB1/NIK cascade , 2003, Nature Cell Biology.
[42] F. Gonzalez,et al. Adipocyte-specific Gene Expression and Adipogenic Steatosis in the Mouse Liver Due to Peroxisome Proliferator-activated Receptor γ1 (PPARγ1) Overexpression* , 2003, The Journal of Biological Chemistry.
[43] P. C. Chin,et al. Akt Is a Downstream Target of NF-κB* , 2002, The Journal of Biological Chemistry.
[44] S. Haffner,et al. Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus , 2002, Circulation.
[45] R. Monteiro,et al. Effect of IgA on respiratory burst and cytokine release by human alveolar macrophages: role of ERK1/2 mitogen-activated protein kinases and NF-kappaB. , 2002, American journal of respiratory cell and molecular biology.
[46] A. Batlle,et al. The effects of some porphyrinogenic drugs on the brain cholinergic system. , 2002, Cellular and molecular biology.
[47] J. Seidell,et al. Epidemiology of obesity. , 2002, Seminars in vascular medicine.
[48] N. Datson,et al. Identification of Differentially Regulated Genes in Mildly Hyperlipidemic ApoE3-Leiden Mice by Use of Serial Analysis of Gene Expression , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[49] W. Hsueh,et al. Troglitazone Inhibits Formation of Early Atherosclerotic Lesions in Diabetic and Nondiabetic Low Density Lipoprotein Receptor–Deficient Mice , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[50] Andrew C. Li,et al. Peroxisome proliferator–activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor–deficient mice , 2000 .
[51] S. Lin,et al. Development of high fat diet-induced obesity and leptin resistance in C57Bl/6J mice , 2000, International Journal of Obesity.
[52] C. Glass,et al. 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[53] P. Kopelman. Obesity as a medical problem , 2000, Nature.
[54] G. Natoli,et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase , 2000, Nature.
[55] Frank J. Gonzalez,et al. Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1* , 1999, The Journal of Biological Chemistry.
[56] Michael Karin,et al. The Beginning of the End: IκB Kinase (IKK) and NF-κB Activation* , 1999, The Journal of Biological Chemistry.
[57] L. Pfeffer,et al. NF-κB activation by tumour necrosis factor requires the Akt serine–threonine kinase , 1999, Nature.
[58] J. Romashkova,et al. NF-κB is a target of AKT in anti-apoptotic PDGF signalling , 1999, Nature.
[59] M. Lazar,et al. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. , 1999, The Journal of clinical investigation.
[60] D. Botstein,et al. Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[61] G. Courtois,et al. Complementation Cloning of NEMO, a Component of the IκB Kinase Complex Essential for NF-κB Activation , 1998, Cell.
[62] L. Havekes,et al. Progression and regression of atherosclerosis in APOE3-Leiden transgenic mice: an immunohistochemical study. , 1997, Atherosclerosis.
[63] J. Egido,et al. Interaction of IgA with Fc alpha receptors of human mesangial cells activates transcription factor nuclear factor-kappa B and induces expression and synthesis of monocyte chemoattractant protein-1, IL-8, and IFN-inducible protein 10. , 1997, Journal of immunology.
[64] A. Koj. Initiation of acute phase response and synthesis of cytokines. , 1996, Biochimica et biophysica acta.
[65] B. Spiegelman,et al. Adipogenesis and Obesity: Rounding Out the Big Picture , 1996, Cell.
[66] B. Spiegelman,et al. ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. , 1996, Genes & development.
[67] K. Ozato,et al. Interferon regulatory factor-2 physically interacts with NF-κB in vitro and inhibits NF-κB induction of major histocompatibility class I and β2-microglobulin gene expression in transfected human neuroblastoma cells , 1995, Journal of Neuroimmunology.
[68] J. Lehmann,et al. An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.
[69] L. Lissner,et al. Dietary fat and obesity: evidence from epidemiology. , 1995, European journal of clinical nutrition.
[70] R. Frants,et al. Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice. , 1994, The Journal of clinical investigation.
[71] R. Frants,et al. Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. , 1993, The Journal of biological chemistry.
[72] J. Jukema,et al. Negative effects of rofecoxib treatment on cardiac function after ischemia-reperfusion injury in APOE3Leiden mice are prevented by combined treatment with thromboxane prostanoid-receptor antagonist S18886 (terutroban). , 2008, Critical care medicine.
[73] T. Luedde,et al. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. , 2007, Cancer cell.
[74] Y. Terauchi,et al. Serum butyrylcholinesterase is strongly associated with adiposity, the serum lipid profile and insulin resistance. , 2007, Internal medicine.
[75] Andy Liaw,et al. Classification and Regression by randomForest , 2007 .
[76] Bradley E. Enerson,et al. Bioinformatics Original Paper Pathway Analysis Using Random Forests Classification and Regression , 2022 .
[77] T. Okumura,et al. Increased expression of PPARgamma in high fat diet-induced liver steatosis in mice. , 2005, Biochemical and biophysical research communications.
[78] S. Shoelson,et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. , 2005, Nature medicine.
[79] M. Hofker,et al. Understanding hyperlipidemia and atherosclerosis: lessons from genetically modified apoe and ldlr mice , 2005, Clinical chemistry and laboratory medicine.
[80] Kunihiro Matsumoto,et al. Cytokines suppress adipogenesis and PPAR-gamma function through the TAK1/TAB1/NIK cascade. , 2003, Nature cell biology.
[81] P. Scheurich,et al. Tumor necrosis factor signaling , 2003, Cell Death and Differentiation.
[82] J. Reddy,et al. Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. , 2003, The Journal of biological chemistry.
[83] P. J. van den Elsen,et al. Regulation of human beta 2-microglobulin transactivation in hematopoietic cells. , 2003, Blood.
[84] P. C. Chin,et al. Akt is a downstream target of NF-kappa B. , 2002, The Journal of biological chemistry.
[85] T. Willson,et al. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. , 2000, The Journal of clinical investigation.
[86] J. Romashkova,et al. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. , 1999, Nature.
[87] G. Courtois,et al. Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation. , 1998, Cell.
[88] J. Lehmann,et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). , 1995, The Journal of biological chemistry.
[89] K. Ozato,et al. Interferon regulatory factor-2 physically interacts with NF-kappa B in vitro and inhibits NF-kappa B induction of major histocompatibility class I and beta 2-microglobulin gene expression in transfected human neuroblastoma cells. , 1995, Journal of neuroimmunology.
[90] G. Reaven,et al. Effects of weight reduction on obesity. Studies of lipid and carbohydrate metabolism in normal and hyperlipoproteinemic subjects. , 1974, The Journal of clinical investigation.